Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
February 20 2024 - 8:00AM
Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced that it will present
final STAR-0215 Phase 1a healthy subject data at the upcoming
American Academy of Allergy, Asthma, & Immunology (AAAAI)
Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm
EST.
Dr. William Lumry, M.D., Clinical Professor of Internal Medicine
at the University of Texas Health Science Center at Dallas, will
present a poster titled, “Updated Results from a Phase 1a Trial of
STAR-0215 for Hereditary Angioedema” at 3:15pm EST in the
Convention Center, Level 2, Hall D, poster number 032.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220427055/en/
Astria:
Investor Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Jul 2023 to Jul 2024